FDA Hoping To Shift Some ‘Cures’ Initiatives Toward User Fee Negotiations
This article was originally published in The Tan Sheet
As Rep. Upton signals an impending deal, FDA Acting Commissioner Stephen Ostroff strikes a more conciliatory tone than his predecessor, Margaret Hamburg.
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Stephen Hahn will go before the Senate health committee less than three weeks after being nominated. Pink Sheet's historical charts illustrate how a long wait and a quick hearing could mean a rapid confirmation.
Oncology, neuroscience, and infectious diseases get acting directors as the expansion and renovation of the Office of New Drugs moves into Phase II.